Examinando por Autor "Urrútia, Gerard"

Mostrando 1 - 4 de 4
  • Miniatura
    Ítem
    Efficacy of systemic oncological treatments in patients with advanced pancreatic cancer at high risk of dying in the short or medium-term: overview of systematic reviews
    (Elsevier, 2021) Salazar, Josefina; Perez-Bracchiglione, Javier; Salas-Gama, Karla; Antequera, Alba; Auladell-Rispau, Ariadna; Dorantes-Romandı, Rosario; Meade, Adriana G.; Quintana, María Jesús; Requeijo, Carolina; Rodrıíguez-Grijalva, Gerardo; Santero, Marilina; Acosta-Dighero, Roberto; Sola, Iván; Urrútia, Gerard; Bonfill Cosp, Xavier
    Background: Patients with advanced pancreatic cancer (PC) have a high risk of dying in the short or medium-term. This overview aimed to assess the evidence regarding systemic oncological treatments (SOT) versus supportive care for advanced PC. Methods: We searched for systematic reviews (SRs) in MEDLINE, Embase, The Cochrane Library, Epistemonikos, and PROSPERO. Two authors assessed eligibility independently. Data extraction and methodological quality assessment were conducted by one author and cross-checked by another one. We evaluated the overlap of primary studies, performed a de novo meta-analysis, and assessed the certainty of evidence. Primary outcomes were overall survival (OS), quality of life (QoL), functional status (FS), and toxicity. Results: We identified three SRs that assessed SOT versus supportive care in patients with advanced PC. All SRs had critically low methodological quality. At 12 months, OS improved with chemotherapy, radiotherapy followed by chemotherapy, and immunotherapy, but the certainty of the evidence supporting these findings is very low. The evidence on chemotherapy is very uncertain about its effects on QoL; it suggests a slight increase in toxicity and little to no difference in FS. The evidence on immunotherapy is very uncertain about its effects in toxicity. Conclusions: The identified evidence is very uncertain about the benefits of oncological treatments on OS and QoL in patients with advanced PC with a high risk of dying in the short or medium-term, so its use should be proposed only to selected patients. Further studies that include a thorough assessment of patient-centred outcomes are needed.
  • Miniatura
    Ítem
    Registered trials address questions already answered with high-certainty evidence: A sample of current redundant research
    (Elsevier, 2021) Vergara-Merino, Laura; Verdejo, Catalina; Ariel Franco, Juan Victor; Escobar Liquitay, Camila; Urrútia, Gerard; Klabundea, Rachel; Pérez, Paulina; Sánchez, Luna; Madrid, Eva
    Objective. To identify clinical trials registered later than 2015, that study the effect of an intervention on a primary outcome whose “Certainty of Evidence” (CoE) has already been rated “high” in a Cochrane SR. Study Design and Setting. We searched the Cochrane Library for all SRs from 2015. We analyzed SRs of interventions and excluded withdrawn reviews or those with no Summary of Findings (SoF) table. We retrieved the GRADE CoE ratings of each SR's primary outcomes in the SoF tables and identified those rated “high.” We searched the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials to identify records of clinical studies that tackled those outcomes and were registered after the date of publication of the respective 2015 SR. Results. We selected 602 SRs. Eighty-one contained a “high” CoE rating on at least one primary outcome, totaling 152 primary outcomes rated “high.” We found 39 clinical trials registered for primary outcomes with evidence already rated as “high” in a 2015 Cochrane SR. Conclusion. This study shows the existence of clinical trials registered to study primary outcomes whose CoE has already been rated “high” in a Cochrane SR.
  • Miniatura
    Ítem
    Stem cell therapy for dilated cardiomyopathy (Review)
    (Cochrane, 2021) Díaz-Navarro, Rienzi; Urrútia, Gerard; Cleland, John Gf; Poloni, Daniel; Villagran, Francisco; Acosta-Dighero, Roberto; Bangdiwala, Shrikant I; Rada, Gabriel; Madrid, Eva
    Background. Stem cell therapy (SCT) has been proposed as an alternative treatment for dilated cardiomyopathy (DCM), nonetheless its effectiveness remains debatable. Objectives. To assess the effectiveness and safety of SCT in adults with non‐ischaemic DCM. Search methods. We searched CENTRAL in the Cochrane Library, MEDLINE, and Embase for relevant trials in November 2020. We also searched two clinical trials registers in May 2020. Selection criteria. Eligible studies were randomized controlled trials (RCT) comparing stem/progenitor cells with no cells in adults with non‐ischaemic DCM. We included co‐interventions such as the administration of stem cell mobilizing agents. Studies were classified and analysed into three categories according to the comparison intervention, which consisted of no intervention/placebo, cell mobilization with cytokines, or a different mode of SCT. The first two comparisons (no cells in the control group) served to assess the efficacy of SCT while the third (different mode of SCT) served to complement the review with information about safety and other information of potential utility for a better understanding of the effects of SCT. Data collection and analysis. Two review authors independently screened all references for eligibility, assessed trial quality, and extracted data. We undertook a quantitative evaluation of data using random‐effects meta‐analyses. We evaluated heterogeneity using the I² statistic. We could not explore potential effect modifiers through subgroup analyses as they were deemed uninformative due to the scarce number of trials available. We assessed the certainty of the evidence using the GRADE approach. We created summary of findings tables using GRADEpro GDT. We focused our summary of findings on all‐cause mortality, safety, health‐related quality of life (HRQoL), performance status, and major adverse cardiovascular events. Main results. We included 13 RCTs involving 762 participants (452 cell therapy and 310 controls). Only one study was at low risk of bias in all domains. There were many shortcomings in the publications that did not allow a precise assessment of the risk of bias in many domains. Due to the nature of the intervention, the main source of potential bias was lack of blinding of participants (performance bias). Frequently, the format of the continuous data available was not ideal for use in the meta‐analysis and forced us to seek strategies for transforming data in a usable format. We are uncertain whether SCT reduces all‐cause mortality in people with DCM compared to no intervention/placebo (mean follow‐up 12 months) (risk ratio (RR) 0.84, 95% confidence interval (CI) 0.54 to 1.31; I² = 0%; studies = 7, participants = 361; very low‐certainty evidence). We are uncertain whether SCT increases the risk of procedural complications associated with cells injection in people with DCM (data could not be pooled; studies = 7; participants = 361; very low‐certainty evidence). We are uncertain whether SCT improves HRQoL (standardized mean difference (SMD) 0.62, 95% CI 0.01 to 1.23; I² = 72%; studies = 5, participants = 272; very low‐certainty evidence) and functional capacity (6‐minute walk test) (mean difference (MD) 70.12 m, 95% CI –5.28 to 145.51; I² = 87%; studies = 5, participants = 230; very low‐certainty evidence). SCT may result in a slight functional class (New York Heart Association) improvement (data could not be pooled; studies = 6, participants = 398; low‐certainty evidence). None of the included studies reported major adverse cardiovascular events as defined in our protocol. SCT may not increase the risk of ventricular arrhythmia (data could not be pooled; studies = 8, participants = 504; low‐certainty evidence). When comparing SCT to cell mobilization with granulocyte‐colony stimulating factor (G‐CSF), we are uncertain whether SCT reduces all‐cause mortality (RR 0.46, 95% CI 0.16 to 1.31; I² = 39%; studies = 3, participants = 195; very low‐certainty evidence). We are uncertain whether SCT increases the risk of procedural complications associated with cells injection (studies = 1, participants = 60; very low‐certainty evidence). SCT may not improve HRQoL (MD 4.61 points, 95% CI –5.62 to 14.83; studies = 1, participants = 22; low‐certainty evidence). SCT may improve functional capacity (6‐minute walk test) (MD 140.14 m, 95% CI 119.51 to 160.77; I² = 0%; studies = 2, participants = 155; low‐certainty evidence). None of the included studies reported MACE as defined in our protocol or ventricular arrhythmia. The most commonly reported outcomes across studies were based on physiological measures of cardiac function where there were some beneficial effects suggesting potential benefits of SCT in people with non‐ischaemic DCM. However, it is unclear if this intermediate effects translates into clinical benefits for these patients. With regard to specific aspects related to the modality of cell therapy and its delivery, uncertainties remain as subgroup analyses could not be performed as planned, making it necessary to wait for the publication of several studies that are currently in progress before any firm conclusion can be reached. Authors' conclusions. We are uncertain whether SCT in people with DCM reduces the risk of all‐cause mortality and procedural complications, improves HRQoL, and performance status (exercise capacity). SCT may improve functional class (NYHA), compared to usual care (no cells). Similarly, when compared to G‐CSF, we are also uncertain whether SCT in people with DCM reduces the risk of all‐cause mortality although some studies within this comparison observed a favourable effect that should be interpreted with caution. SCT may not improve HRQoL but may improve to some extent performance status (exercise capacity). Very low‐quality evidence reflects uncertainty regarding procedural complications. These suggested beneficial effects of SCT, although uncertain due to the very low certainty of the evidence, are accompanied by favourable effects on some physiological measures of cardiac function. Presently, the most effective mode of administration of SCT and the population that could benefit the most is unclear. Therefore, it seems reasonable that use of SCT in people with DCM is limited to clinical research settings. Results of ongoing studies are likely to modify these conclusions.
  • Miniatura
    Ítem
    Taxanes for advanced non-small cell lung cancer (Protocol)
    (Cochrane, 2018) Madrid, Eva; Barros Monge, Manuel J; Urrútia, Gerard; Roqué I Figuls, Marta; Pérez Bracchiglione, Javier; Vargas Peirano, Manuel; Loézar Hernández, Cristóbal Nicolás; Bonfill Cosp, Xavier
    This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of taxanes as part of a combined or single‐agent therapy versus other agents or best supportive care as first‐ or second‐line treatment for advanced non‐small cell lung cancer (NSCLC). A secondary objective is to assess different modes or schemes of administration of taxanes in patients with this disease.